<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082940</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-27102</org_study_id>
    <secondary_id>CDR0000361734</secondary_id>
    <secondary_id>CCCWFU-BG02-331</secondary_id>
    <secondary_id>LIGAND-CCCWFU-27102</secondary_id>
    <nct_id>NCT00082940</nct_id>
  </id_info>
  <brief_title>Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Study of ONTAK® (Denileukin Diftitox, DABIL-2) in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as denileukin diftitox, may interfere with the growth&#xD;
      of cancer cells and slow the growth of chronic lymphocytic leukemia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating&#xD;
      patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the complete and partial response rate in patients with fludarabine-refractory&#xD;
           B-cell chronic lymphocytic leukemia treated with denileukin diftitox.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the response rate in patients (regardless of CD25 receptor density) treated&#xD;
           with this drug.&#xD;
&#xD;
        -  Determine the progression-free survival and overall survival of patients treated with&#xD;
           this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive denileukin diftitox IV over 1 hour on days 1-5. Treatment repeats every 21&#xD;
      days for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients achieving a complete response after 8 courses proceed to follow-up. Patients&#xD;
      achieving a partial response or stable disease after 8 courses may continue treatment at the&#xD;
      discretion of the investigator.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then annually until relapse.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-44 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denileukin diftitox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL) meeting the following criteria&#xD;
             at any time during the course of disease (e.g., at initial diagnosis or relapse):&#xD;
&#xD;
               -  Absolute lymphocytosis &gt; 5,000/mm^3&#xD;
&#xD;
               -  Lymphocytes must appear mature with &lt; 55% prolymphocytes&#xD;
&#xD;
               -  More than 30% of all nucleated cells are lymphoid on bone marrow aspirate smear&#xD;
&#xD;
               -  Lymphoid infiltrates compatible with bone marrow involvement by CLL on core bone&#xD;
                  marrow biopsy&#xD;
&#xD;
               -  Predominant B-cell monoclonal population of cells share the B-cell marker (CD19)&#xD;
                  with the CD5 antigen in the absence of other pan-T-cell markers by lymphocyte&#xD;
                  immunophenotyping&#xD;
&#xD;
          -  High-risk disease OR intermediate-risk disease&#xD;
&#xD;
               -  Patients in the intermediate-risk group must have evidence of active disease as&#xD;
                  demonstrated by at least 1 of the following criteria:&#xD;
&#xD;
                    -  Massive or progressive splenomegaly and/or adenopathy&#xD;
&#xD;
                    -  Weight loss &gt; 10% within the past 6 months&#xD;
&#xD;
                    -  Common toxicity grade 2-4 fatigue&#xD;
&#xD;
                    -  Fevers &gt; 100.5°F OR night sweats for more than 2 weeks without evidence of&#xD;
                       infection&#xD;
&#xD;
                    -  Progressive lymphocytosis with an increase of &gt; 50% over a 2-month period or&#xD;
                       an anticipated doubling time of &lt; 6 months&#xD;
&#xD;
          -  Failed at least 1 prior fludarabine regimen, as defined by 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Refractory or intolerant to fludarabine&#xD;
&#xD;
               -  Relapsed within 6 months after completion of fludarabine&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
          -  No mantle cell lymphoma in leukemic phase&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Albumin ≥ 3 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  No hepatitis B or C infection&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other concurrent serious illness&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use two effective methods of contraception (one must be&#xD;
             non-hormonal) during and for at least 1 month after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior denileukin diftitox allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids as anti-emetics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 28 days since prior anticancer therapy and recovered&#xD;
&#xD;
          -  No other concurrent antineoplastic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur E. Frankel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph Hospital Regional Cancer Center - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3849</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Vincennes</name>
      <address>
        <city>Vincennes</city>
        <state>Indiana</state>
        <zip>47591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gibbs Regional Cancer Center at Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology and Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Regional Cancer Center - Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer. 2006 May 15;106(10):2158-64.</citation>
    <PMID>16586495</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2004</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denileukin diftitox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

